It has been found that high PD-L1 expression was significantly correlated with the presence of KRAS mutations in pulmonary sarcomatous carcinoma and lung adenocarcinoma [58, 59], indicating that patients with KRAS mutations may exhibit a more efficient response to ICB. Here, KRAS is linked to lung adenocarcinoma.